| Literature DB >> 35490440 |
I Backhaus1, D Hermsen2, J Timm3, F Boege2, N Lübke3, T Degode4, K Göbels4, N Dragano5.
Abstract
OBJECTIVES: Most SARS-CoV-2 seroprevalence studies have focussed on adults and high-risk populations, and little is known about young adults. The objective of the present study was to provide evidence on the SARS-CoV-2 seroprevalence among young adults in Germany and to explore determinants associated with seropositivity in general and, specifically, with previously undetected infections. STUDYEntities:
Keywords: COVID-19; SARS-CoV-2 antibodies; Seroprevalence; Young adults
Mesh:
Substances:
Year: 2022 PMID: 35490440 PMCID: PMC8940565 DOI: 10.1016/j.puhe.2022.03.009
Source DB: PubMed Journal: Public Health ISSN: 0033-3506 Impact factor: 4.984
Fig. 1Flow diagram of participant recruitment, enrolment, and study completion.
Sociodemographic characteristics of study participants (n = 2186).
| Characteristics | Participants, |
|---|---|
| Sex | |
| Female | 1327 (60.7) |
| Male | 857 (39.2) |
| Missing | 2 (0.1) |
| Age group | |
| <20 years | 139 (6.4) |
| 20–25 years | 813 (37.2) |
| 26–30 years | 1218 (55.7) |
| Missing | 16 (0.7) |
| Household size | |
| 1 person | 575 (26.3) |
| 2 persons | 1027 (47.0) |
| ≥3 persons | 567 (25.9) |
| Missing | 17 (0.8) |
| Educational level | |
| Lower and middle | 171 (7.8) |
| Higher | 1921 (87.9) |
| Still a student or other type of education | 81 (3.7) |
| Missing | 13 (0.6) |
| Employment status | |
| Not working | 110 (5.0) |
| Part-time and short-term (reduced working hours) | 164 (7.5) |
| Full time | 1180 (54.0) |
| Student | 703 (32.2) |
| Missing | 29 (1.3) |
| Migration background | |
| Yes | 370 (16.9) |
| No | 1803 (82.5) |
| Missing | 13 (0.6) |
Participants' education level was assessed according to the 2011 version of the International Standard Classification of Education (ISCED) and grouped into low/middle education (e.g. primary education) and higher education.
This also includes pensioners and parents on maternity leave.
Health-related characteristics and social determinants of study participants (n = 2186).
| Characteristics | Participants, |
|---|---|
| Self-reported health | |
| Very good/excellent | 1771 (81.0) |
| Fair/bad | 385 (17.6) |
| Missing | 30 (1.4) |
| Chronic condition | |
| No | 1975 (90.3) |
| Yes | 201 (9.2) |
| Missing | 10 (0.5) |
| PCR test since February 2020 | |
| Yes | 784 (35.9) |
| No, no test needed | 1126 (51.5) |
| No, but I thought about getting tested | 194 (8.9) |
| No, I asked for a test but did not get one | 72 (3.3) |
| Missing | 10 (0.5) |
| Self-reported COVID-19 | |
| Yes | 46 (2.1) |
| No | 728 (33.3) |
| I do not know | 10 (0.4) |
| Symptoms since February 1 | |
| Fever ≥38 °C | 225 (10.3) |
| Cough | 648 (29.8) |
| Pneumonia | 7 (0.3) |
| Dyspnoea/shortness of breath | 121 (5.6) |
| Pain when breathing | 112 (5.2) |
| Congested/running nose | 848 (39.0) |
| Sore throat | 854 (39.1) |
| Loss of smell or taste | 100 (4.6) |
| No symptoms | 511 (23.5) |
| Contact to a confirmed COVID-19 case | |
| No | 1711 (78.3) |
| Yes, with a distance ≥1.5 m | 179 (8.2) |
| Yes, with a distance <1.5 m | 285 (13.0) |
| Missing | 11 (0.5) |
| Other exposures | |
| Working with patients | 262 (12.0) |
| Working with customers | 340 (15.6) |
| Participated in an event with ≥50 persons | 850 (39.1) |
| Travelled outside the EU | 246 (11.3) |
| Travelled within the EU | 1068 (49.0) |
| General adherence to public health measures | |
| Adheres completely to public health measures | 1243 (56.9) |
| Adheres partly to public health measures | 919 (42.0) |
| Adheres little to public health measures | 9 (0.4) |
| Does not adhere to public health measures at all | 0 (0.0) |
| Missing | 15 (0.7) |
| COVID-19 information resource: social media | |
| Rarely/never | 1488 (68.1) |
| Often/always | 686 (31.4) |
| Missing | 12 (0.5) |
| Trust in COVID-19 information from social media influencer | |
| Trust | 277 (12.7) |
| No trust | 1891 (86.5) |
| Missing | 18 (0.8) |
| Supporting social distancing in private (contact restriction) | |
| Yes | 1968 (90.0) |
| No | 204 (9.4) |
| Missing | 14 (0.6) |
| Supporting social distancing in public (at least 1.5 m distance) | |
| Yes | 2126 (97.3) |
| No | 488 (2.2) |
| Missing | 12 (0.5) |
| Supporting wearing a face mask in public spaces | |
| Yes | 2165 (99.0) |
| No | 13 (0.6) |
| Missing | 8 (0.4) |
| Supporting the travel restriction | |
| Yes | 1991 (91.1) |
| No | 169 (7.7) |
| Missing | 26 (1.2) |
PCR, polymerase chain reaction.
Multiple replies were possible.
In the following analyses, the categories "partly" and "little" were categorised as "partly, adherence to public health measures was assessed by asking respondents.
Comparison of different prevalence measures of SARS-CoV-2 antibodies (n = 2186).
| Prevalence measure | SARS-CoV-2 seroprevalence (unadjusted, | SARS-CoV-2 seroprevalence (adjusted | Participants with neutralising antibodies titres |
|---|---|---|---|
| Overall seroprevalence | 3.3 (2.6–4.1) | 3.1 (2.4–4.0) | 3.0 (2.4–3.8) |
| Percentage of those who are seropositive and had a positive PCR before study | 2.1 (1.6–2.8) | 1.9 (1.4–2.6) | N/A |
| Percentage of those with neutralising antibody titres and a positive PCR before study | 45.5 (34.0–57.4) | 45.0 (34.1–57.6) | N/A |
CI, confidence interval; N/A, not applicable.
Adjusted for Roche Cobas Elecsys Anti-SARS-CoV-2 test sensitivity and specificity.
Only in case of a positive Roche Cobas Elecsys Anti-SARS-CoV-2 test (n = 66) neutralising antibody titre assay was performed.
SARS-CoV-2 seroprevalence in young adults and determinants of infection (n = 2186).
| Characteristic | Distribution among seropositive participants | OR for being seropositive unadjusted | OR for being seropositive adjusted for age and sex | Distribution among seropositive participants, but without prior self-reported SARS-CoV-2 infection (positive by PCR) |
|---|---|---|---|---|
| % | OR [95% CI] | OR [95% CI] | % | |
| Sex | ||||
| Male | 3.8% [2.7–5.3]; 34 | Ref | Ref | 2.6% [1.7–3.9]; 23 |
| Female | 2.7% [1.9–3.7]; 38 | 0.70 [0.42–1.15] | 0.70 [0.42–1.16] | 1.3% [0.7–2.0]; 18 |
| Missing ( | 0 | – | – | 0 |
| Age group | ||||
| <20 years | 2.7% [0.9–7.0]; 4 | Ref | Ref | 2.0% [0.6–6.2]; 3 |
| 20–25 years | 3.4% [2.3–4.9]; 29 | 1.27 [0.4–3.9] | 1.30 [0.6–2.0] | 2.2% [1.13–3.5]; 19 |
| 26–30 years | 2.9% [2.0–4.0]; 37 | 1.07 [0.4–3.3] | 0.94 [0.4–2.0] | 1.3% [0.8–2.2]; 18 |
| Missing ( | 2 | – | – | 1 |
| Household size | ||||
| 1 person | 3.1% [1.9–4.9]; 19 | Ref | Ref | 1.6% [0.8–3.1]; 10 |
| 2 persons | 3.2% [2.3–4.6]; 35 | 1.03 [0.6–1.9] | 1.06 [0.6–2.0] | 1.8% [1.1–2.9]; 20 |
| ≥3 persons | 2.8% [1.7–4.6]; 17 | 0.90 [0.4–1.8] | 0.94 [0.6–2.0] | 1.6% [0.8–3.1]; 10 |
| Missing ( | 1 | – | – | 1 |
| Educational level | ||||
| Lower/middle | 2.7% [1.1–6.5]; 5 | Ref | Ref | 1.0% [0.1–4.2]; 2 |
| Higher | 3.2% [2.4–4.1]; 64 | 1.15 [0.4–2.9] | 1.52 [0.50–4.63] | 1.9% [1.2–2.5]; 37 |
| Still a student/other degree | 2.3% [0.5–8.4]; 2 | 0.83 [0.1–5.0] | 1.10 [0.17–7.18] | 2.3% [0.5–8.4]; 2 |
| Missing ( | 1 | – | – | 0 |
| Employment status | ||||
| Full time | 3.1% [2.2–4.3]; 39 | Ref | Ref | 1.7% [1.1–2.7]; 22 |
| Not working | 5.3% [2.3–11.3]; 6 | 1.73 [0.7–4.3] | 1.88 [0.7–4.7] | 2.7% [0.8–8.1]; 3 |
| Part-time or reduced working hours | 4.1% [1.9–8.4]; 7 | 1.32 [0.6–3.1] | 1.43 [0.6–3.4] | 12 |
| Student | 2.2% [1.3–3.7]; 17 | 0.71 [0.4–1.32] | 0.71 [0.4–1.3] | 1.7% [0.9–3.1]; 13 |
| Missing | 3 | – | – | 4.4% [2.3–21.7]; 1 |
| Migration background | ||||
| No | 3.2% [2.4–4.1]; 60 | Ref | Ref | 1.6% [1.1–4.1]; 32 |
| Yes | 2.5% [1.3–4.7]; 10 | 0.79 [0.4–1.62] | 0.81 [0.4–1.65] | 1.8% [0.7–3.8]; 7 |
| Missing ( | 2 | – | – | 2 |
CI, confidence interval; OR, odds ratio.
The estimates for household size, education, employment status and migration background are adjusted for age and sex, the estimate for age is adjusted only for sex and the estimate for sex is adjusted for age only.
For the analysis of subjects with antibodies but without self-reported SARS-CoV-2 infection, subjects with positive PCR test (n = 46) or unknown PCR result (n = 10) were excluded, resulting in a sample size of 2130 participants.
This is the test-adjusted seroprevalence; row-percentages.
Ref = reference category.